A Study of Immunogenicity and Efficacy by quadrivalent Influenza Vaccination in Inflammatory Bowel Disease Patients

A Study of Immunogenicity and Efficacy by quadrivalent Influenza Vaccination in Inflammatory Bowel Disease Patients - Efficacy of Influenza Vaccination in Inflammatory Bowel Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018975

Enrollment

230

Registered

2015-10-06

Start date

2015-10-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

Serum antibody titers obtained prior to vaccination and 4~6 weeks after the first and second dose of quadrivalent influenza vaccine were tested to Inflammatory bowel disease patients, and efficacy wer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subjects who are able to follow the regulation of the trial and written informed consent can be obtained from patients or their legal guardian.

Exclusion criteria

Exclusion criteria: 1) Pregnant patients. 2) patients with hypersensitivity to influenza vaccine. 8) Subjects judged as inadequate by the researchers.

Design outcomes

Primary

Measure	Time frame
Serum antibody titers were measured prior to the first injection and after the first injection or the second injection (4~6 weeks starting with the first injection) and 4~6 weeks after the second dose and after influenza epidemic(HI antibody against influenza A and B)	—

Countries

Japan

Contacts

Public ContactShinpei Shirai

Saga University Hospital Internal medicine of Gastroenterology

totoronin1029@gmail.com0952-31-6511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026